MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia. (Q54498929)

30 May 2018

title

MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia. (English)

1 reference

30 May 2018

1 reference

4

1 reference

30 May 2018

Oliver Ottmann

5

1 reference

30 May 2018

author name string

F J Giles

1

1 reference

30 May 2018

R T Swords

2

1 reference

30 May 2018

A Nagler

3

1 reference

30 May 2018

D A Rizzieri

6

1 reference

30 May 2018

M Talpaz

7

1 reference

30 May 2018

J Clark

8

1 reference

30 May 2018

P Watson

9

1 reference

30 May 2018

A Xiao

10

1 reference

30 May 2018

B Zhao

11

1 reference

30 May 2018

D Bergstrom

12

1 reference

30 May 2018

P D Le Coutre

13

1 reference

30 May 2018

S J Freedman

14

1 reference

30 May 2018

J E Cortes

15

1 reference

30 May 2018

publication date

9 July 2012

1 reference

30 May 2018

published in

Leukemia

1 reference

30 May 2018

volume

27

1 reference

30 May 2018

issue

1

1 reference

30 May 2018

page(s)

113-117

1 reference

30 May 2018

https://scigraph.springernature.com/pub.10.1038/leu.2012.186

exact match

0 references

cites work

Therapeutic advances in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.186

Making the Auroras glow: regulation of Aurora A and B kinase function by interacting proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.186

The chromosomal passenger complex: one for all and all for one.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.186

The cellular geography of aurora kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.186

Cell cycle-dependent expression and centrosome localization of a third human aurora/Ipl1-related protein kinase, AIK3

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.186

Update on Aurora Kinase Targeted Therapeutics in Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.186

A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.186

Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.186

Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.186

Aurora A and B kinases--targets of novel anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.186

Aurora B: a new prognostic marker and therapeutic target in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.186

VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.186

VX-680 inhibits Aurora A and Aurora B kinase activity in human cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.186

The discovery of the potent aurora inhibitor MK-0457 (VX-680).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.186

Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.186

Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.186

Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.186

Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.186

Mechanism of MK-0457 efficacy against BCR-ABL positive leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.186

HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.186

The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.186

Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.186

Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.186

Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.186

A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.186

Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.186

Activity of the Aurora kinase inhibitor VX-680 against Bcr/Abl-positive acute lymphoblastic leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.186

The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.186

Targeting aurora kinases in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.186

The potential role of Aurora kinase inhibitors in haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.186

MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.186

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/LEU.2012.186

1 reference

30 May 2018

PubMed ID

22772060

1 reference

30 May 2018